- Home
- ESGL vs CGTX Comparison
ESGL vs CGTX Comparison
Compare ESGL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- CGTX
- Stock Information
- Founded
- ESGL 1999
- CGTX 2007
- Country
- ESGL Singapore
- CGTX United States
- Employees
- ESGL N/A
- CGTX N/A
- Industry
- ESGL
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ESGL
- CGTX Health Care
- Exchange
- ESGL Nasdaq
- CGTX Nasdaq
- Market Cap
- ESGL 71.6M
- CGTX 79.3M
- IPO Year
- ESGL N/A
- CGTX 2021
- Fundamental
- Price
- ESGL $1.75
- CGTX $0.44
- Analyst Decision
- ESGL
- CGTX Buy
- Analyst Count
- ESGL 0
- CGTX 6
- Target Price
- ESGL N/A
- CGTX $8.00
- AVG Volume (30 Days)
- ESGL 6.2K
- CGTX 476.7K
- Earning Date
- ESGL 12-03-2024
- CGTX 11-13-2024
- Dividend Yield
- ESGL N/A
- CGTX N/A
- EPS Growth
- ESGL N/A
- CGTX N/A
- EPS
- ESGL N/A
- CGTX N/A
- Revenue
- ESGL $6,218,838.00
- CGTX N/A
- Revenue This Year
- ESGL N/A
- CGTX N/A
- Revenue Next Year
- ESGL N/A
- CGTX N/A
- P/E Ratio
- ESGL N/A
- CGTX N/A
- Revenue Growth
- ESGL 20.34
- CGTX N/A
- 52 Week Low
- ESGL $0.41
- CGTX $0.34
- 52 Week High
- ESGL $2.23
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- ESGL 43.30
- CGTX 41.17
- Support Level
- ESGL $1.50
- CGTX $0.43
- Resistance Level
- ESGL $1.88
- CGTX $0.48
- Average True Range (ATR)
- ESGL 0.12
- CGTX 0.04
- MACD
- ESGL -0.01
- CGTX -0.01
- Stochastic Oscillator
- ESGL 52.87
- CGTX 7.26
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd Formerly Environmental Solutions Group Holdings Ltd is a waste management, treatment and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical and electroplating companies.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.